Icon (ICLR)

• Market cap: $17.1B
• 1 day: 1.42%
• 5 days: 0.19%
• 1 month: 1.89%
• 3 months: -31.53%
• 6 months: -34.33%
• Year to date: -26.10%
• 1 year: -25.73%
• 5 years: 21.07%
• 10 years: 296.69%

About: Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.

Employees: 42,250

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

313% more call options, than puts

Call options by funds: $82.9M | Put options by funds: $20.1M

0.2% less ownership

Funds ownership: 93.76% [Q2] → 93.56% (-0.2%) [Q3]

5% less repeat investments, than reductions

Existing positions increased: 234 | Existing positions reduced: 246

3% less funds holding

Funds holding: 666 [Q2] → 649 (-17) [Q3]

9% less capital invested

Capital invested by funds: $24.3B [Q2] → $22B (-$2.24B) [Q3]

20% less first-time investments, than exits

New positions opened: 66 | Existing positions closed: 83

42% less funds holding in top 10

Funds holding in top 10: 26 [Q2] → 15 (-11) [Q3]

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $225 8% upside
• Avg. target: $283 36% upside
• High target: $350 69% upside

9 analyst ratings

• positive: 7 78%
• neutral: 2 22%
• negative: 0 0%

Truist Securities Jailendra Singh 14% 1-year accuracy 5 / 35 met price target	37% upside $284	Buy Reiterated	18 Dec 2024
Baird Eric Coldwell 32% 1-year accuracy 11 / 34 met price target	8% upside $225	Neutral Maintained	20 Nov 2024
Leerink Partners Michael Cherny 58% 1-year accuracy 19 / 33 met price target	23% upside $255	Outperform Reiterated	19 Nov 2024
TD Cowen Charles Rhyee 22% 1-year accuracy 2 / 9 met price target	37% upside $285	Buy Maintained	25 Oct 2024
Barclays Luke Sergott 27% 1-year accuracy 13 / 48 met price target	33% upside $275	Overweight Maintained	25 Oct 2024